GlassScriptPhysician profile
Derek I Mito
NPI 1558335042
$5,119.98
in general payments reported to CMS, 2019-2025
22 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.74 · 2020: $514 · 2021: $500 · 2022: $465 · 2023: $245 · 2024: $1,169 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,566.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $785.09 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $769.88 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $569.52 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $553.52 | 2020-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.50 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $434.00 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $320.89 | 2020-2025 | |
| Abbvie INC. | $258.04 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $251.98 | 2025 | Ponvory, Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $183.39 | 2024-2025 | |
| Esperion Therapeutics, INC. | $120.98 | 2024-2025 | Nexletol |
| Gilead Sciences, INC. | $88.54 | 2025 | |
| Merck Sharp & Dohme LLC | $57.60 | 2020-2021 | |
| Inspire Medical Systems, INC. | $43.01 | 2025 | Inspire |
| Corcept Therapeutics | $33.77 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.26 | 2019-2020 | |
| Exact Sciences Corporation | $26.01 | 2025 | The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $23.53 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.03 | 2025 | Rexulti |
| Amarin Pharma, INC. | $19.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Mito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.